NCT02096289View on ClinicalTrials.gov

Safety Study of Thioridazine in Combination With Cytarabine to Treat Relapsed or Refractory Acute Myeloid Leukemia

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

August 31, 2016

Study Completion Date

September 30, 2016

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

Thioridazine

Trial Locations (1)

L8V 1C3

Juravinski Hospital & Cancer Centre, Hamilton

All Listed Sponsors

collaborator

Hamilton Health Sciences Corporation

OTHER

collaborator

Juravinski Cancer Centre Foundation

OTHER

lead

Ontario Clinical Oncology Group (OCOG)

OTHER

NCT02096289 - Safety Study of Thioridazine in Combination With Cytarabine to Treat Relapsed or Refractory Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter